April 27, 1999

Contact:
Angie Thorell
MDS Harris
402-476-2811

Contact:
Nancy Lawrence
Media Relations, LHSC
519-685-8500, ext. 74772

 

MDS Harris expands Site Management Organization at London Health Sciences Centre

(LONDON, Ontario) In a joint venture with London Health Sciences Centre (LHSC) of London, Ontario, MDS Harris has expanded its Site Management Organization (SMO) into Canada, and will conduct clinical research for pharmaceutical and biotechnology companies. The LHSC location is the first MDS Harris SMO in Canada.

"London Health Sciences Centre is one of Canada's leading academic medical centres, with extensive therapeutic expertise complementary to MDS Harris that is in high demand in the field of clinical research," said Matt Harris, vice-president, SMO, of MDS Harris. "We are delighted to work with this prestigious organization."

A Site Management Organization approach provides centralized coordination of research sites, centralized processes and information systems, clinical laboratory services, and data management, as well as the ability to conduct outpatient, inpatient, and large studies.

London Health Sciences Centre is one of Canada's largest teaching hospitals dedicated to excellence in patient care, teaching and research. LHSC, which includes the Children's Hospital of Western Ontario, has a capacity of 762 beds and 53 bassinets. The staff of approximately 7,000 care for more than half a million inpatient, outpatient and emergency patients annually. Spread over three million square feet of property, LHSC is located on two campuses at three sites. Further, LHSC has gained national and international recognition for therapeutic expertise in a wide number of areas including: oncology care, cardiac care, clinical neurological sciences, critical care and trauma services, medical imaging and MRI, multi-organ transplantation, orthopedic/sports medicine, pediatric care, reproductive medicine, and women's health.

"Combining LHSC's therapeutic expertise and patient population base with our 66 years of experience and proprietary ClinQuick, a real-time data acquisition system, will provide the accurate, reliable, on-time results our industry clients depend upon," says Harris.

"The addition of this dedicated SMO site is another example of how academic medical centres and industry can work together to advance science," says Dr. Joe Gilbert, vice-president, research, LHSC.

MDS Harris, headquartered in Lincoln, Neb., is an operating unit of MDS Drug Discovery and Development Sector, a division of MDS Inc., the second-largest clinical research organization in the world.

MDS Inc. (MHG.A, MHG.B) is a Canadian-based, international health and life sciences company. Its core purpose is to make a distinctive contribution to the health and well-being of people. MDS employs more than 7000 highly-skilled people at its global operations in Canada and the United States, as well as in Northern Ireland, England, Belgium, Switzerland, Germany, South Africa, Japan, Taiwan, and Chine. The core businesses of MDS include: the production and distribution of diagnostic and therapeutic radioisotopes; the provision of laboratory information and management, and patented laboratory automation and software; drug discovery and development services for the world's biotechnology and pharmaceutical industries; manufacturing of ultra-trace detection equipment; and medical and hospital supplies and inventory management systems. Detailed information about the company is available at the MDS website at http://www.mdsintl.com or by calling 1-800-MDS-7222.

EDITORS/REPORTERS NOTE: A Phase I drug study involves testing a new drug on human volunteers and screening for any adverse reactions. A Phase II drug study involves giving the drug to target populations to determine the most effective dosages. A Phase III study is an analysis of the drug in the target population in a controlled, clinical trial. Phase IV is the careful analysis of the widespread use of the drug.

About Us

Last Updated June 13, 2007 | © 2007, LHSC, London Ontario Canada